Israel Englander’s Capricor Therapeutics CAPR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.01M Buy
+125,000
New +$3.79M ﹤0.01% 3471
2025
Q4
Sell
-200,500
Closed -$1.45M 6040
2025
Q3
$1.45M Buy
200,500
+160,500
+401% +$1.18M ﹤0.01% 4335
2025
Q2
$397K Buy
+40,000
New +$423K ﹤0.01% 5049
2024
Q4
Sell
-24,100
Closed -$367K 5983
2024
Q3
$367K Buy
+24,100
New +$119K ﹤0.01% 5064

Other funds holding CAPR

Israel Englander's CAPR Position: Q2 2026 in Review

Israel Englander reduced its Capricor Therapeutics (CAPR) stake by 34% in Q2 2026, selling an estimated $3.71M and leaving 233,926 shares worth $5.63M. The position accounts for ﹤0.01% of the portfolio, ranked #2879.

Israel Englander first reported a position in CAPR in Q1 2015 and has held it in 23 quarters since. The position peaked at $19.7M in Q4 2025. 169 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • Israel Englander held 233,926 shares of Capricor Therapeutics worth $5.63M as of Q2 2026.
  • Israel Englander sold 122,428 Capricor Therapeutics shares in Q2 2026, an estimated $3.71M.
  • Capricor Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #2879 holding.
  • Israel Englander first reported a position in Capricor Therapeutics in Q1 2015 and has held it in 23 quarters since.
  • Israel Englander's Capricor Therapeutics position peaked at $19.7M in Q4 2025.
  • 169 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.